BDSI’s BEMA medication delivery technology receives Canada patent BioDelivery Sciences International, Inc. announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive medication delivery technology in Canada from 2017 to 2027.S. For the treating moderate to serious chronic discomfort. 2,658,585 provides extra exclusivity associated with formulation characteristics for improved medication absorption from the BEMA medication delivery technology., a jv between BDSI’s industrial partner Meda, and Valeant Canada Small.Celiac disease is definitely a serious, incurable condition that afflicts around 1 % of children and 1.2 % of adults across the United States. People with celiac disease suffer severe and dangerous digestive reactions to gluten potentially, the major protein within wheat and many other grains. ‘It really is generally approved that the activation of the disease fighting capability by gluten peptides is in charge of pathogenesis and progression of celiac disease,’ the researchers wrote. ‘Within the last 10 years the results of many investigations showed that gluten corrupts the. Antioxidant stability in intestinal mucosa, probably by an overproduction of free radicals.’ To help expand investigate this connection between celiac disease, free antioxidants and radicals, the experts performed intestinal biopsies on 39 children with either active or silent celiac disease and on 19 healthful controls of equivalent age.